You are here:

  1. Home

Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template

  • NICE process and methods
  • Reference number: PMG24
  • Published:  08 January 2015
  • Last updated:  03 December 2024
  • Process
  • Tools and resources
Download (PDF)
  • Overview
  • Instructions for companies
  • 1 Decision problem, description of the technology and clinical care pathway
  • 2 Clinical effectiveness
  • 3 Cost effectiveness
  • 4 References
  • 5 Appendices
  • Appendix A: Summary of product characteristics (SmPC) and UK public assessment report
  • Appendix B: Identification, selection and synthesis of clinical evidence
  • Appendix C: Subgroup analysis
  • Appendix D: Adverse reactions
  • Appendix E: Published cost-effectiveness studies
  • Appendix F: Health-related quality-of-life studies
  • Appendix G: Cost and healthcare resource identification, measurement and valuation
  • Appendix H: Clinical outcomes and disaggregated results from the model
  • Appendix I: Price details of treatments included in the submission
  • Update information

Appendix F: Health-related quality-of-life studies

Describe how systematic searches for relevant health-related quality-of-life data were done. Consider published and unpublished studies, including any original research commissioned for the technology. Provide the rationale for terms used in the search strategy and any inclusion and exclusion criteria used. The search strategy used should be provided in the appendix.

Tabulate the details of the studies in which health-related quality of life was measured. Include the following, but note that this list is not exhaustive:

  • population in which health effects were measured

  • information on recruitment (for example, participants of a clinical trial, approximations from clinical experts, utility elicitation exercises including members of the general public or patients)

  • interventions and comparators

  • sample size

  • response rates

  • description of health states

  • adverse reactions

  • appropriateness of health states given the condition and treatment pathway

  • method of elicitation

  • method of valuation

  • mapping

  • uncertainty around values

  • consistency with reference case.

See section 3.4.3.


Next page Appendix G: Cost and healthcare resource identification, measurement and valuation Previous page Appendix E: Published cost-effectiveness studies
Back to top